Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

227
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
227
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

130
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
130
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

192
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
192
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

133
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
133
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

228
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
228
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

138
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
138

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A.Kocher Technique: A Simplified Universally Applicable Approach for Aortic Root Enlargement.

Innovations (Philadelphia, Pa.)·2026
Same author

Open Type A Aortic Dissection Repair: Toward Consensus End Points in Thoracic Aortic Surgery.

The Annals of thoracic surgery·2026
Same author

CT-Based Annular Dimensions in Transcatheter Mitral Valve Replacement: A Multicenter Registry Study.

The Annals of thoracic surgery·2026
Same author

The 10 Commandments for Oral Anticoagulation After Tissue Valve Replacement.

Innovations (Philadelphia, Pa.)·2026
Same author

Transcatheter Versus Minimally Invasive Surgical Aortic Valve Replacement With Rapid-Deployment Valves: A Propensity-Matched Analysis.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same author

Quantifying the enamine-type nucleophilic reactivity of α-aryl vinyl azides.

Chemical communications (Cambridge, England)·2026

Related Experiment Video

Updated: Nov 29, 2025

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.4K

Structural valve deterioration after aortic valve replacement with the Trifecta valve.

Paul Werner1, Jasmin Gritsch1, Sabine Scherzer1

  • 1Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.

Interactive Cardiovascular and Thoracic Surgery
|November 22, 2020
PubMed
Summary

This study found a high rate of structural valve deterioration (SVD) in Trifecta valves used for surgical aortic valve replacement (SAVR). These findings suggest reduced prosthesis durability over time, necessitating reintervention for SVD.

Keywords:
Bioprosthetic dysfunctionStructural valve deteriorationSurgical aortic valve replacement

More Related Videos

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.1K
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.6K

Related Experiment Videos

Last Updated: Nov 29, 2025

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.4K
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.1K
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.6K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Surgical Innovation

Background:

  • The Trifecta valve has shown promising short- and mid-term results for surgical aortic valve replacement (SAVR).
  • However, conflicting reports regarding early structural valve deterioration (SVD) necessitate further investigation into its long-term durability.

Purpose of the Study:

  • To investigate the incidence of structural valve deterioration (SVD) after SAVR using the Trifecta valve.
  • To assess the long-term durability and reintervention rates associated with Trifecta valve implantation.

Main Methods:

  • A retrospective analysis of 347 consecutive patients undergoing SAVR with the Trifecta valve between 2011 and 2017.
  • Clinical and echocardiographic data were collected with a median follow-up of 41 months (1114 patient-years).

Main Results:

  • Structural valve deterioration (SVD) was observed in 7.2% of patients, with a median time to diagnosis of 73 months.
  • Freedom from SVD was 92.5% at 5 years and 65.5% at 7 years.
  • Thirteen patients (3.7%) required reintervention for SVD, with freedom from reintervention at 7 years being 76.9%.

Conclusions:

  • This study reports a high rate of SVD after SAVR with the Trifecta valve, indicating decreased prosthesis durability.
  • The findings highlight the need for careful monitoring and suggest potential limitations in the long-term performance of the Trifecta valve, leading to significant reintervention rates.